Skip to main content
ADC Therapeutics SA logo

ADC Therapeutics SA — Investor Relations & Filings

Ticker · ADCT ISIN · CH0499880968 US Manufacturing
Filings indexed 396 across all filing types
Latest filing 2025-12-15 Regulatory Filings
Country US United States of America
Listing US ADCT

About ADC Therapeutics SA

https://adctherapeutics.com/

ADC Therapeutics SA is a commercial-stage biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for cancer therapy. The company focuses on creating highly potent and targeted ADCs to treat hematologic malignancies and solid tumors, addressing significant unmet medical needs. Its primary product, ZYNLONTA® (loncastuximab tesirine-lpyl), is an FDA-approved anti-CD19 ADC for adults with relapsed or refractory large B-cell lymphoma. The company's research and development pipeline includes a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker, aimed at treating solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-12-15 English
FORM 424B3
Regulatory Filings
2025-12-12 English
FORM 4
Director's Dealing
2025-12-09 English
FORM 4
Director's Dealing
2025-12-09 English
FORM 4
Director's Dealing
2025-12-09 English
FORM 4
Director's Dealing
2025-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.